南美洲和中美洲地尔硫卓市场预测至 2028 年 - COVID-19 影响和按产品类型(胶囊、注射剂和片剂)和应用(心绞痛、高血压等)进行的区域分析

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 134    |    Report Code: TIPRE00025363    |    Category: Life Sciences

South and Central America Diltiazem Market

市场介绍

地尔硫卓是一种苯并硫氮杂卓衍生物,具有抗高血压和血管扩张作用。地尔硫卓是一种抗高血压和血管扩张剂,通过放松血管肌肉来降低血压。这是由于降低血压具有长期治疗作用,因为它降低了致命和非致命心血管事件(如中风和心肌梗塞)的风险。根据体外结合实验,地尔硫卓与血浆蛋白的结合率为70%-80%。在临床相关浓度下,大约 40% 的药物被认为与 α-1-糖蛋白结合,而大约 30% 的药物被认为与白蛋白结合。

市场概况与动态

南美洲和中美洲地尔硫卓市场预计从2021年的2682万美元增至2028年的5703万美元;预计 2021 年至 2028 年复合年增长率为 11.4%。政府推广举措的增加、心血管疾病患病率的增加以及全球患有心脏病的老年人口的增加预计将推动市场增长年。然而,地尔硫卓对消费的副作用可能会对未来几年的市场增长产生负面影响。

地尔硫卓具有治疗多种心血管疾病的潜在用途。据世界卫生组织称,心血管疾病(CVD)是全球第一大死亡原因。心血管疾病是发病的主要原因,影响的人数比任何其他疾病都多。吸烟、不健康饮食和缺乏身体活动是增加心脏病和中风风险的主要生活方式因素。此外,其他可能导致心血管疾病的危险因素还有高血压、糖尿病和胆固醇水平升高。钙通道阻滞剂地尔硫卓(Cardizem)和维拉帕米(Calan 和 Apoptin)可有效控制房颤患者的初始心室率。这些药物以推注剂量静脉内给药,直到心室率变慢。

此外,地尔硫卓可减少房室结的传导,这对于患有以下疾病的患者的心率控制也很有用:心房颤动。因此,全球心房颤动患病率的不断上升推动了地尔硫卓市场的发展。根据《2019年全球老龄化》调查,2019年全球65岁及以上人口总数为7.03亿。到2050年,老年人口预计将翻一番,达到15亿。此外,老年人口更容易出现非典型表现、合并症,以及不利的结果。与衰老相关的心血管系统的结构和功能变化是心血管疾病的主要原因。因此,全球老年人口的增加导致心血管疾病发病率增加,从而促进了地尔硫卓市场的增长。

COVID-19 疫情严重影响了南美洲和中美洲的医疗服务。 COVID-19的突然爆发导致多个国家实施了严格的封锁规定,导致地尔硫卓的进出口活动中断。此外,这些国家以医疗旅游闻名,这也受到了疫情的影响。预计该地区可能会强制实施第二次封锁,这最终将阻碍该地区的医疗保健行业。在这次 COVID-19 大流行期间,人们进行了大量尝试探索药物疗法来预防和治疗 SARS-CoV-2 感染。因此,该地区正在进行的有关地尔硫卓治疗 COVID-19 的临床研究可能有利于市场的适度增长。

 

主要细分市场

根据产品,南美洲和中美洲地尔硫卓市场分为胶囊、注射剂和片剂。 2021年,平板电脑细分市场占据最大市场份额。然而,预计2021年至2028年胶囊细分市场的复合年增长率最快。

根据应用,南美洲和中美洲地尔硫卓市场分为心绞痛、高血压和其他的。 2021年,高血压细分市场占据最大市场份额。预计未来几年心绞痛细分市场将以最快的复合年增长率增长。

 

< span>主要来源和上市公司

与本报告有关的南美洲和中美洲地尔硫卓市场相关的一些主要和二手来源是巴西地理与统计研究所 (IBGE)、阿根廷心脏病学会 (SAC) 和疾病控制与预防中心 (CDC) 等。

 < /span>

购买报告的理由

  • 根据未来几年南美洲和中美洲地尔硫卓市场的详细趋势分析确定潜在投资领域。
  • 深入了解推动支出最高的国家/地区不同成瘾治疗药物细分市场需求的根本因素,并确定每个细分市场提供的机会
  • 加强您对市场需求驱动因素、行业趋势和最新技术发展等方面的了解。
  • 确定推动南美洲和中美洲地尔硫卓市场的主要渠道 提供未来机会的清晰画面,有助于分析、从而扩大收入。
  • 通过重点关注南亚和南亚地区不同国家正在进行的项目来引导资源 中美洲地尔硫卓市场

 

南部和中美洲地尔硫卓市场细分

按产品类型

  • 片剂
  • 胶囊
  • 注射剂

应用

  • 高血压
  • < li>心绞痛
  • 其他

按国家/地区

  • 巴西
  • 阿根廷
  • 南部和中部其他地区美国

公司简介

  • Bausch Health Companies Inc.
  • 梯瓦制药工业有限公司
  • MYLAN NV
  • 辉瑞公司.
  • 山德士(诺华公司)
  • 太阳制药工业有限公司
  • < span>Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark


South and Central America Diltiazem Strategic Insights

Strategic insights for South and Central America Diltiazem involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/south-and-central-america-diltiazem-market-strategic-framework.webp
Get more information on this report

South and Central America Diltiazem Report Scope

Report Attribute Details
Market size in 2021 US$ 26.82 Million
Market Size by 2028 US$ 57.03 Million
Global CAGR (2021 - 2028) 11.4%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By 产品类型
  • 胶囊
  • 注射剂
  • 片剂
By 应用
  • 心绞痛
  • 高血压
Regions and Countries Covered 南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
Market leaders and key company profiles
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
  • Get more information on this report

    South and Central America Diltiazem Regional Insights

    The regional scope of South and Central America Diltiazem refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/south-and-central-america-diltiazem-market-geography.webp
    Get more information on this report

    The List of Companies - South and Central America Diltiazem Market

    1. Bausch Health Companies Inc.
    2. Teva Pharmaceutical Industries Ltd
    3. MYLAN N.V.
    4. Pfizer Inc.
    5. Sandoz (Novartis AG)
    6. Sun Pharmaceutical Industries Ltd
    7. Hikma Pharmaceuticals PLC
    8. Zydus Cadila
    9. Glenmark
    Frequently Asked Questions
    How big is the South and Central America Diltiazem Market?

    The South and Central America Diltiazem Market is valued at US$ 26.82 Million in 2021, it is projected to reach US$ 57.03 Million by 2028.

    What is the CAGR for South and Central America Diltiazem Market by (2021 - 2028)?

    As per our report South and Central America Diltiazem Market, the market size is valued at US$ 26.82 Million in 2021, projecting it to reach US$ 57.03 Million by 2028. This translates to a CAGR of approximately 11.4% during the forecast period.

    What segments are covered in this report?

    The South and Central America Diltiazem Market report typically cover these key segments-

  • 产品类型 (胶囊, 注射剂, 片剂)
  • 应用 (心绞痛, 高血压)
  • What is the historic period, base year, and forecast period taken for South and Central America Diltiazem Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Diltiazem Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in South and Central America Diltiazem Market?

    The South and Central America Diltiazem Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
  • Who should buy this report?

    The South and Central America Diltiazem Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the South and Central America Diltiazem Market value chain can benefit from the information contained in a comprehensive market report.